Trials / Withdrawn
WithdrawnNCT02006849
ACTH Treatment of APOL1- Associated Nephropathy
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine if the study drug H.C. Acthar gel slows the progression of your kidney disease. This drug is a steroid-based medicine with fewer side effects than other steroids used for treatment of kidney diseases similar to APOL1 nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acthar | FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2013-12-10
- Last updated
- 2017-11-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02006849. Inclusion in this directory is not an endorsement.